4-cresol-sulfate and Hyperphosphatemia

P-cresyl sulfate and indoxyl sulfate are strongly associated with cardiovascular events and all-cause mortality in chronic kidney disease (CKD). This randomized controlled trial was conducted to compare the effects between sevelamer and calcium carbonate on protein-bound uremic toxins in pre-dialysis CKD patients with hyperphosphatemia. Forty pre-dialysis CKD patients with persistent hyperphosphatemia were randomly assigned to receive either 2400 mg of sevelamer daily or 1500 mg of calcium carbonate daily for 24 weeks. A significant decrease of total serum p-cresyl sulfate was observed in sevelamer therapy compared to calcium carbonate therapy (mean difference between two groups -5.61 mg/L; 95% CI -11.01 to -0.27 mg/L;

Topics: Calcium Carbonate; Chelating Agents; Cresols; Female; Humans; Hyperphosphatemia; Indican; Male; Middle Aged; Renal Insufficiency, Chronic; Sevelamer; Sulfuric Acid Esters; Uremic Toxins